Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC.

Cancers (Basel) · 2022 · PMC9221141 · PMID 35740564

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

a trend towards significancep = 0.12not close (p > 0.1)

NR, HR 0.29 CI 95% 0.10–0.86, p = 0.02) and a trend towards significance in PFS (5.0 vs. 14.2 months, HR 0.43, CI 95% 0.15–1.25, p = 0.12) ( Figure 1 e).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.